Free Trial
NASDAQ:DWTX

Dogwood Therapeutics Q4 2024 Earnings Report

Dogwood Therapeutics logo
$4.83 +0.07 (+1.47%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.78 -0.05 (-1.14%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dogwood Therapeutics EPS Results

Actual EPS
-$6.29
Consensus EPS
-$1.49
Beat/Miss
Missed by -$4.80
One Year Ago EPS
N/A

Dogwood Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dogwood Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
1:30PM ET

Upcoming Earnings

Dogwood Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Dogwood Therapeutics Earnings Headlines

Comparing Dogwood Therapeutics (DWTX) & Its Competitors
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
DWTX Dogwood Therapeutics, Inc.
See More Dogwood Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email.

About Dogwood Therapeutics

Dogwood Therapeutics (NASDAQ:DWTX) (NASDAQ:DWTX) is a clinical-stage biotechnology company dedicated to developing first-in-class small-molecule therapies that harness the body’s own repair mechanisms to treat acute and chronic tissue injuries. The company’s proprietary approach focuses on modulating endogenous progenitor cell mobilization from the bone marrow and other reservoirs to sites of damaged tissue, offering a potentially more durable and cost-effective alternative to cell therapy or biologics. Through selective engagement of key signaling pathways, Dogwood’s programs aim to accelerate healing and restore function in a range of indications.

At the core of Dogwood’s pipeline are multiple preclinical and early clinical candidates designed to address unmet needs in wound healing, cardiac repair and organ fibrosis. Its lead program is advancing through Phase 1/2 trials in diabetic wound healing, where standard of care options remain limited. Additional programs are exploring applications in ischemic heart disease and renal injury, with preclinical data demonstrating enhanced vascularization, reduced inflammation and improved tissue remodeling. Dogwood’s small-molecule platform enables convenient oral dosing and scalable manufacturing, positioning its candidates for broad clinical adoption.

Founded in 2019 as a spin-out from pioneering research in regenerative medicine, Dogwood Therapeutics is headquartered in Redwood City, California, with research facilities in Cambridge, UK. The company collaborates with leading academic institutions and clinical sites across North America and Europe to accelerate translational studies and validate clinical endpoints. Partnerships with contract research organizations and specialized manufacturing providers further support Dogwood’s ability to move programs efficiently through toxicology, formulation and early-stage trials.

Under the leadership of a seasoned management team with deep expertise in drug discovery, clinical development and commercial strategy, Dogwood is building a foundation for long-term growth. Its executives bring prior experience from leading biotechnology and pharmaceutical companies, as well as track records in advancing novel therapies from laboratory to market. With a clear focus on regenerative pharmacology and strategic collaborations, Dogwood Therapeutics is positioned to deliver innovative treatment options for patients with limited alternatives in tissue repair and recovery.

View Dogwood Therapeutics Profile

More Earnings Resources from MarketBeat